Mr. Stephen Van Deventer reports

PREVECEUTICAL FILES TWO FAMILY PATENTS OF SOL-GEL CANNABINOID FORMULATION AND ANTIVIRAL USE & CYCLIC PEPTIDES AND USES THEREOF

Preveceutical Medical Inc. is furthering the progress of two of its patent families.

The patent family based on PCT/AU2021/051383 (P114915, Sol-Gel cannabinoid formulation and anti-viral use) has now entered the national phase in Europe and Australia. The Australian case has been allocated application No. 2021384063, and the European case has been allocated application No. EP21893149.1. This is in addition to patent applications having recently been filed in the United States and Canada.

Preveceutical's patent family based on PCT/AU2021/051545 (P113135.PCT, cyclic peptides and uses thereof) has now entered the national phase in the U.S. and Canada. The U.S. case has been allocated the application No. US18/268951, and full filing details in Canada are awaited.

Preveceutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continues its clinical process.

Preveceutical's chief executive officer, Stephen Van Deventer, commented, "We continue to aggressively prosecute patents in all major jurisdictions globally to ensure our IP is well protected."

Although Preveceutical believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate or successful.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The company aims to be a leader in the preventive health sciences sector.

With the completion of three of its research programs, the company is actively working on the development, clinical trials and commercialization of its products, and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.